首页> 外文会议>International Conference on Food Science and Technology >Elementary Study on Producing Pharmaceutical Fungi with New Solid Fermentation Engineering
【24h】

Elementary Study on Producing Pharmaceutical Fungi with New Solid Fermentation Engineering

机译:新型固体发酵工程生产药物真菌的基本研究

获取原文

摘要

As a new research field of modern biology technology, the new solid fermentation engineering has a huge potentiality in the development of medicinal materials and utilization of biologic resources. In this paper, a study on producing three pharmaceutical fungi (Ganoder-ma lucidum Karst, Polystictus vesicolor (L.) Fr. , Grifola frondosa(Fr.) S. F. Gray) with herb residues as raw materials was made under the guide of new solid fermentation engineering, and the mam bioactive components (fungal polysaccharide, water-soluable protein, triter-pense)in medicinal fungal substance were measured and analysed. The results showed that as follows: firstly, there was a close relation among mycelium growth , the content of bioactive components(polysaccharide, water-soluable protein, ganoderic acid) and mycelium meba-tolism in fermentation process, but the changes were not completely synchronous ; secondly, ganoderic acid produced in fermentation process was less than that in fruitbody in both kind and content, so it was deduced that their producing ganoderic acid mechanism was probably different; thirdly, it was an effective approach to obtain fungal polysaccharide by solid fermentation with herb residues as raw materials.
机译:作为现代生物技术的新研究领域,新的固体发酵工程在药用材料的发展和生物资源利用中具有巨大潜力。本文在制造三种药物真菌(Ganoder-ma lucidum karst,Polystirtus vesicolor(L.)fr.,Grifola frondosa(fr.)Sf灰色),用草本植物为原料,在新的固体引导下进行测量并分析了药物真菌物质中的发酵工程和MAM生物活性组分(真菌多糖,水溶性蛋白质,三级键)。结果表明,如下:首先,菌丝体生长,生物活性成分的含量(多糖,水溶性蛋白质,灵芝酸)和发酵过程中的菌丝MEBA-TOLIS,但变化并不完全同步;其次,在发酵过程中产生的灵芝酸小于种类和含量的水果体中的酸,所以推导出它们的生产的灵芝酸机制可能是不同的;第三,通过用草本残留物作为原料,通过固体发酵获得真菌多糖的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号